Weekly Investment Analysts’ Ratings Updates for Rhythm Pharmaceuticals (RYTM)

Several brokerages have updated their recommendations and price targets on shares of Rhythm Pharmaceuticals (NASDAQ: RYTM) in the last few weeks:

• 11/10/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $105.00 to $114.00. They now have a “buy” rating on the stock.
• 11/8/2025 – Rhythm Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/5/2025 – Rhythm Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings, Inc. from an “outperform” rating to a “market perform” rating.
• 11/4/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $95.00 to $122.00. They now have a “buy” rating on the stock.
• 10/17/2025 – Rhythm Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $139.00. They now have a “buy” rating on the stock.
• 10/16/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $122.00 to $129.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/29/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at HC Wainwright from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 9/27/2025 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/25/2025 – Rhythm Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 9/25/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at JMP Securities from $135.00 to $142.00. They now have a “market outperform” rating on the stock.
• 9/24/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $109.00 to $122.00. They now have an “overweight” rating on the stock.
• 9/24/2025 – Rhythm Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $105.00 to $138.00. They now have a “buy” rating on the stock.

Insider Transactions at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 3,477 shares of the stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $96.00, for a total value of $333,792.00. Following the transaction, the chief financial officer directly owned 116,915 shares of the company’s stock, valued at $11,223,840. This represents a 2.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joseph Shulman sold 9,748 shares of the business’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the sale, the insider owned 8,509 shares of the company’s stock, valued at approximately $980,577.16. This represents a 53.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 34,665 shares of company stock worth $3,817,375. 6.10% of the stock is owned by insiders.

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.